<DOC>
	<DOCNO>NCT01472003</DOCNO>
	<brief_summary>This open label study design evaluate biodistribution image characteristic ABT-806i ( 111In-ABT-806 ) subject advance solid tumor type .</brief_summary>
	<brief_title>An Evaluation Biodistribution Imaging Characteristics ABT-806i ( 111In-ABT-806 ) Subjects With Advanced Solid Tumor Types</brief_title>
	<detailed_description />
	<criteria>Subject solid tumor type likely know either overexpress wildtype Epidermal Growth Factor Receptor ( EGFR ) express variant III mutant EGFR ( e.g. , head neck squamous cell carcinoma , Nonsmall Cell Lung Carcinoma ( NSCLC ) , colorectal carcinoma ) . Subject must disease amenable surgical resection approve therapeutic option curative intent . Subject tolerate must eligible approve therapeutic option know survival advantage . Subject Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 2 . Subject must measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 least 1 extrahepatic 2 cm lesion . Subject receive anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal , biologic , investigational therapy within period 14 day prior first dose ABT806i . Subject receive prior EGFRdirected monoclonal antibody within period 4 week prior first dose ABT806i . Subject unresolved clinically significant toxicity prior anticancer therapy , define Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 high . Subject major surgery within 21 day prior first dose ABT806i . Subject clinically significant uncontrolled condition ( ) include limited following : Active uncontrolled infection Symptomatic congestive heart failure Unstable angina pectoris cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>